About JXR Company

The Group is a leading ARS supplier in China and the US. According to a market research report on the ARS market in China and the US prepared by the Shanghai branch of Frost Sullivan (Beijing) Consulting Co., Ltd. (“Frost Sullivan Report”), assisted reproductive health institutions within the Group's Chinese network ranked third in the Chinese ARS market in 2018, and carried out 20,958 IVF egg retrieval cycles, accounting for about 3.1% of the total market share in China. According to the same indicators, these institutions also ranked first among non-state ARS suppliers in China in 2018. HRC Fertility (including HRCMedical managed by HRC Management under a management service agreement) ranked first in the Western US ARS market in 2018. With the Group's leading position in the existing markets in China and the US, the Group has a unique advantage of being able to seize the unmet needs of ARS patients in China and the US and the growth opportunities of the two markets. The Group is committed to providing patients with personalized solutions to fulfill their dream of becoming parents. The Group has established a competitive advantage in brand, technology, medical teams and management in markets with significant barriers to entry. All hospitals established within the Group's network are recognized as first-class in their respective regional markets (including but not limited to Sichuan Province, the Greater Bay Area, Yunnan Province and the Western United States), which helps the Group to take a leading position in the Chinese and US ARS markets. In 2021, the Group acquired Jinxin Women and Children's Hospital, Hong Kong Fertility Health Center (brand name: Thanksgiving Medical Center) and Hong Kong Assisted Fertility Center to expand its footprint in Sichuan Province and the Greater Bay Area, and expand its scope of services to provide services throughout the childbearing cycle, including pregnancy preparation, IVF, antenatal, delivery and post-natal services. In the first half of 2023, with the advantages of ARS, the Group's core business, the Group further expanded its scope of services by integrating its ARS, obstetrics, and pediatric services to create synergies and increase its control over Shenzhen Zhongshan Hospital. We believe that by utilizing our existing resources and continuously recruiting talents and elites to join the Group, we can replicate our success in the new regions we have already entered. The Group expects that as the Chinese government implements support policies and support measures to encourage childbearing (including the “Decision on Optimizing Fertility Policies to Promote Long-term Balanced Population Development” issued in July 2021), the penetration rate and market size of ARS in China will increase significantly. Therefore, in order to seize the opportunities that have arisen, the company has made multiple acquisitions in 2021 and the first half of 2023, and the Group has strategically developed itself into providing medical services that support the entire life cycle of childbearing and pregnancy, preparing for the overall growth of ARS in China. The company aims to continuously expand its hospital network and benefit more people with high-quality ARS, which also helps to strengthen our leading position in the ARS market in China and the US.